Abbott Laboratories shares dropped more than 10% after the company reported Q4 2025 revenue of $11.45 billion — missing Wall Street's consensus by 2.8% — as weakness in its nutrition and diagnostics segments overshadowed strong medical device performance. Full-year 2025 revenue reached $44.3 billion, up 5.7% on a reported basis, but the miss was concentrated in the U.S. nutrition business, where sales fell 13% year-over-year and pediatric nutrition specifically plunged 18%. The primary culprit: the loss of a major WIC (Women, Infants, and Children) government contract that had anchored Abbott's infant formula market share for years. Adjusted EPS met estimates, but the top-line miss and softer 2026 guidance sent the stock into a 10% single-day decline, erasing roughly $20 billion in market cap.

The WIC contract loss is particularly damaging because the federal program covers approximately half of all infant formula purchased in the United States. When a state switches its WIC contract to a competitor — typically Reckitt Benckiser's Enfamil — the incumbent loses not just the WIC-subsidized volume but also the halo effect on retail purchases, as WIC-eligible families tend to stick with the brand their benefits cover. Abbott's Similac franchise, which had been rebuilding trust after the 2022 Sturgis plant shutdown, now faces a structural volume headwind that management acknowledged will take several quarters to lap. The company guided to 2026 adjusted EPS of $5.55-$5.80 with organic sales growth of 7% at the midpoint — respectable numbers that were nonetheless below what the Street had modeled.

For healthcare investors and operators, Abbott's results highlight the hidden fragility of government contract dependency. The WIC program, while providing stable baseline volume, creates winner-take-all dynamics at the state level that can swing hundreds of millions in revenue with a single procurement decision. The parallel to dental is instructive: practices heavily reliant on a single large payer — whether Medicaid, a dominant insurer, or a DSO management agreement — face similar concentration risk when contract terms shift. Abbott's medical device segment, which delivered strong growth driven by new FDA clearances in electrophysiology, structural heart, and diabetes care, provided a buffer — a reminder that product diversification remains the best defense against segment-specific shocks.

Watch for Abbott's Q1 2026 results to determine whether the nutrition decline is stabilizing or accelerating. Key metrics include U.S. pediatric nutrition market share data from Nielsen, any commentary on additional WIC contract bid outcomes, and whether the medical device segment can sustain its growth trajectory to offset nutrition weakness. The company's FreeStyle Libre continuous glucose monitor — now used by over 6 million people globally — remains Abbott's crown jewel growth driver, and its performance will likely determine whether the stock can recover from the post-earnings selloff. Also monitor whether the broader 2026 guidance of 7% organic growth holds or gets revised downward in subsequent quarters.